Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

8.440 +0.190 (+2.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 197,080
Open 8.200
Bid (Size) 7.940 (1)
Ask (Size) 8.980 (1)
Prev. Close 8.250
Today's Range 8.130 - 8.480
52wk Range 6.510 - 14.34
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Expectations for Evolus's Future
 
Via Benzinga
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From Evolus
Via Business Wire

Performance

YTD
+7.79%
+7.79%
1 Month
-4.74%
-4.74%
3 Month
+29.45%
+29.45%
6 Month
+4.58%
+4.58%
1 Year
-27.74%
-27.74%

More News

Read More
Earnings Scheduled For March 8, 2023
Via Benzinga
Preview: Evolus's Earnings
Via Benzinga
Evolus to Participate in the Barclays Global Healthcare Conference
From Evolus
Via Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
From Evolus, Inc.
Via Business Wire
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines
Via Benzinga
Why Evolus Shares Jumped This Week
Via The Motley Fool
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Evolus Not Affected by Recent Korean Court Ruling
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Evolus to Participate in the SVB Securities Global Biopharma Conference
From Evolus
Via Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
From Evolus
Via Business Wire
Evolus Receives Regulatory Approval for Nuceiva® in Australia
From Evolus
Via Business Wire
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
From Evolus
Via Business Wire
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
Via Benzinga
Why Evolus Shares Are Trading Higher Today
Via Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
From Evolus
Via Business Wire
Evolus Extends Term of Credit Facility with Pharmakon Advisors
From Evolus
Via Business Wire
Evolus Reports Third Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Participate in November Conferences
From Evolus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.